Shanghai Startup Raises RMB 330M as China’s Invasive BCI Race Goes Clinical
Shanghai Prosynx Technologies, a six-month-old invasive brain-computer interface company incubated by Lingang Laboratory, has closed a RMB 330 million (US$45.8 million) angel round — the largest single-tranche angel financing in China's BCI sector on record — signaling that the industry's competitive axis has shifted from laboratory benchmarks to clinical translation capability.
The August 3 announcement marks a decisive escalation in China's invasive BCI funding landscape. The round was led by SICC, with co-investors including Lenovo Star, JMC Capital, Daotong Capital, InnoAngel Fund, BGI Pine Health Fund, JF Capital, and Jiado Capital — a syndicate of eight institutions that collectively validates the deal's credibility beyond any single backer's conviction. The financing dwarfs the previous record of RMB 150 million (US$20.8 million) held by Gestalt Technology, raising the benchmark by 2.2 times.
Market context sharpens the significance. Wiraxon disclosed a series round exceeding RMB 300 million (US$41.7 million) in May 2026, while Gestalt Technology subsequently raised RMB 420 million (US$58.3 million) in an angel-plus round. Neither qualifies under the strict single-tranche angel standard, leaving Prosynx's RMB 330 million as the uncontested record on that metric.
1,024 Channels Raises the Technical Bar — But Clinical Proof Remains Elusive
Prosynx's flagship product, the "Tianshu" motor BCI system, achieved 1,024-channel resolution and obtained China's first type-inspection certificate for a same-specification invasive BCI system in November 2025, approximately three months before the company's formal incorporation in February 2026. The system targets patients with motor and language dysfunction caused by stroke, spinal cord injury, and amyotrophic lateral sclerosis (ALS), aiming to decode neural signals and enable external device control.
The 1,024-channel specification is a meaningful engineering milestone. It places Tianshu in the same order of magnitude as leading international implantable BCI platforms, providing the theoretical bandwidth for high-resolution motor decoding and human-machine interaction. However, channel count is a necessary but insufficient proxy for clinical value. The metrics that will ultimately determine the product's worth are effective channel yield post-implantation, long-term signal stability as glial scarring progresses, wireless power and data transmission reliability outside laboratory conditions, and — most critically — reproducible functional improvement in human subjects.
A type-inspection certificate confirms that a device performs to its design specification under controlled conditions. It does not answer whether the device is safe at scale, whether outcomes are durable, or whether the surgical and training workflow can be standardized across clinical sites. Those answers require human trial data that Prosynx has not yet generated.
Capital Buying Time, Not Outcomes: Deconstructing the RMB 330M Deployment
The scale of the raise reflects the capital intensity intrinsic to invasive BCI development rather than commercial traction. A regulatory-grade implantable BCI system requires simultaneous engineering closure across flexible electrode fabrication, analog front-end circuitry, application-specific integrated circuits (ASICs), wireless telemetry, hermetic packaging, neural decoding algorithms, surgical instrumentation, and clinical software. Any single open loop prevents forward progression.
Prosynx currently operates approximately 2,500 square meters of office and GMP clean-room space. Proceeds from this round will fund expansion to a new headquarters exceeding 10,000 square meters by end-2026, incorporating a micro- and nano-fabrication platform, alongside headcount growth to over 100 employees. This allocation profile reveals that the round is funding platform and organizational infrastructure — not merely product development — consistent with a company that needs to compress five to seven years of capability-building into a single funding cycle.
Regulatory economics reinforce this logic. Invasive BCI devices are regulated as Class III medical devices in China, the highest-risk category. The pathway from prototype to clinical product requires quality management system establishment, animal validation, registered clinical trials, and long-term safety follow-up — a process that cannot be executed by a lean team and cannot be meaningfully accelerated by capital alone beyond a certain threshold.
Three-Pipeline Strategy Amplifies Platform Value and Execution Risk Simultaneously
Prosynx has publicly committed to three parallel BCI product lines: motor function restoration, visual reconstruction, and emotion regulation. The platform rationale is coherent — flexible electrode technology, implant chip design, wireless communication architecture, and portions of the signal processing stack are shareable across modalities. If the underlying platform matures, incremental cost to address additional indications is theoretically lower than building from scratch.
The leadership structure is designed to bridge the research-to-product gap. CEO Wu Guojia brings more than 16 years of medical device industry experience, including roles at Boston Scientific and as Executive Director and Vice President at Venus Medtech, with a track record spanning Class III device development, clinical trials, regulatory submission, and commercialization. The core technical team is led by Drs. Jia Jing, Zhao Bin, and Yi Guoliang from Lingang Laboratory, supported by a scientific advisory board covering neuroscience, flexible electronics, algorithms, wireless energy, and optogenetics.
The three-pipeline ambition, however, introduces compounding execution risk at an early stage. Motor BCI, visual BCI, and emotion/psychiatric BCI map to different implantation targets, neural mechanisms, patient populations, surgical protocols, clinical endpoints, and regulatory risk-benefit frameworks. Visual cortex stimulation involves encoding complexity that exceeds motor decoding; emotion regulation intersects with psychiatric disease mechanisms, long-term neuromodulation effects, and a higher bar for ethical review. Running three independent clinical development programs simultaneously would strain any organization at 100 employees.
The more defensible sequencing is to prioritize Tianshu's first human implant, establish a reproducible clinical signal, and then leverage the shared platform for subsequent indications. At this stage, demonstrating one validated product is categorically more valuable than asserting three simultaneous development tracks.
Lingang Lab Incubation Model Faces Its Productization Test
Prosynx's origin as a Lingang Laboratory spinout represents an emerging model for Chinese deep-tech commercialization — one that differs structurally from the traditional university lab startup path. Under the laboratory incubation model, the parent institution builds long-term foundational capability and shared infrastructure; the spinout company absorbs commercializable assets and raises independent capital to build engineering and clinical teams. In principle, this provides a more complete technology foundation at inception than a university group starting from scratch.
The translation gap, however, is real and frequently underestimated. Laboratory systems optimize for novelty and performance at the frontier; medical device development optimizes for batch consistency, sterilization compatibility, packaging integrity, and verifiable long-term reliability. An electrode that performs in an acute animal model must survive gamma irradiation, cold-chain logistics, and multi-year in vivo exposure. An algorithm that achieves high decoding accuracy on a curated dataset must generalize across patients, sessions, and environmental conditions. The engineering work between those two states is substantial and does not compress easily.
Prosynx's ability to establish clear intellectual property boundaries with Lingang Laboratory, develop stable and scalable manufacturing processes, and build decision-making mechanisms driven by clinical need rather than scientific ambition will determine how much of the laboratory's accumulated capability actually converts to product value. This is simultaneously a test of the company and a test of China's high-tier research platform commercialization model more broadly.
Impact Assessment: What the Record Round Signals for China's BCI Ecosystem
The emergence of a RMB 330 million angel round in invasive BCI — alongside Shenfu Jianxing, Gestalt Technology, Stairway Medical, and Zhiran Medical all securing large early-stage rounds in 2026 — indicates that capital allocation in China's BCI sector is migrating from peripheral applications toward core device components, system platforms, and registered clinical programs. This is a structurally positive development: it suggests investors are pricing the full regulatory and clinical development cycle rather than betting on laboratory demonstrations alone.
The key variables to monitor over the next 18 to 24 months are: the timing and patient selection criteria for Tianshu's first-in-human implant; effective channel yield and signal durability at six and twelve months post-implantation; whether the GMP manufacturing platform can achieve consistent output; and whether the company establishes a clear clinical priority ordering across its three product lines.
RMB 330 million buys Prosynx time and infrastructure. It does not buy clinical outcomes. In invasive BCI, the distance between a funding record and a validated therapy is measured in years of human data — and that clock cannot be shortened by any amount of capital.
Related Coverage:
China's BCI Race Heats Up as BrainCo and Neuracle Eye IPOs, Funding Jumps 230%